Sangamo Free Cash Flow Yield vs Average Inventory Analysis
SGMO Stock | USD 1.94 0.01 0.51% |
Sangamo Therapeutics financial indicator trend analysis is much more than just breaking down Sangamo Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sangamo Therapeutics is a good investment. Please check the relationship between Sangamo Therapeutics Free Cash Flow Yield and its Average Inventory accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.
Free Cash Flow Yield vs Average Inventory
Free Cash Flow Yield vs Average Inventory Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sangamo Therapeutics Free Cash Flow Yield account and Average Inventory. At this time, the significance of the direction appears to have pay attention.
The correlation between Sangamo Therapeutics' Free Cash Flow Yield and Average Inventory is -0.98. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Average Inventory in the same time period over historical financial statements of Sangamo Therapeutics, assuming nothing else is changed. The correlation between historical values of Sangamo Therapeutics' Free Cash Flow Yield and Average Inventory is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Sangamo Therapeutics are associated (or correlated) with its Average Inventory. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Average Inventory has no effect on the direction of Free Cash Flow Yield i.e., Sangamo Therapeutics' Free Cash Flow Yield and Average Inventory go up and down completely randomly.
Correlation Coefficient | -0.98 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Average Inventory
The average amount of inventory a company holds over a certain period, which is used to calculate inventory turnover and efficiency in managing stock levels.Most indicators from Sangamo Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sangamo Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.As of the 12th of December 2024, Selling General Administrative is likely to grow to about 64.2 M, though Tax Provision is likely to grow to (4.3 M).
2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 17.6M | 20.6M | 24.6M | 14.1M | Net Interest Income | 5.3M | 9.4M | 13.3M | 7.9M |
Sangamo Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Sangamo Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Sangamo Therapeutics fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 637.5M | 938.6M | 721.9M | 562.5M | 165.3M | 218.1M | |
Total Stockholder Equity | 432.7M | 497.4M | 375.3M | 295.0M | 82.9M | 144.6M | |
Retained Earnings | (657.0M) | (778.0M) | (956.3M) | (1.1B) | (1.4B) | (1.3B) | |
Other Assets | 10.6M | 15.1M | 16.8M | 18.5M | 1.0 | 0.95 | |
Common Stock Shares Outstanding | 112.1M | 134.4M | 144.6M | 154.3M | 174.4M | 183.2M | |
Liabilities And Stockholders Equity | 637.5M | 938.6M | 721.9M | 562.5M | 165.3M | 218.1M | |
Other Stockholder Equity | 1.1B | 1.3B | 1.3B | 1.5B | 1.5B | 1.6B | |
Total Liab | 204.8M | 441.2M | 346.6M | 267.6M | 82.4M | 73.5M | |
Short Long Term Debt Total | 44.4M | 42.1M | 48.1M | 43.1M | 38.1M | 30.0M | |
Other Current Liab | 21.3M | 127.3M | 28.4M | 33.4M | 27.9M | 14.0M | |
Total Current Liabilities | 69.9M | 143.5M | 127.9M | 111.7M | 47.7M | 34.0M | |
Property Plant And Equipment Net | 107.2M | 112.4M | 124.7M | 125.5M | 52.9M | 29.2M | |
Accounts Payable | 6.7M | 12.6M | 9.8M | 22.4M | 15.3M | 16.0M | |
Cash | 80.4M | 131.3M | 178.9M | 100.4M | 45.2M | 45.0M | |
Non Current Assets Total | 232.0M | 278.9M | 323.2M | 262.2M | 71.0M | 68.1M | |
Non Currrent Assets Other | 4.0M | 7.9M | 10.2M | 12.3M | 18.1M | 19.0M | |
Cash And Short Term Investments | 385.0M | 692.0M | 464.7M | 277.6M | 81.0M | 77.0M | |
Net Receivables | 37.6M | 6.3M | 6.4M | 4.5M | 1.3M | 1.3M | |
Common Stock Total Equity | 1.2M | 1.4M | 1.5M | 1.7M | 1.5M | 1.4M | |
Short Term Investments | 282.0M | 510.1M | 197.7M | 177.2M | 35.8M | 34.0M | |
Non Current Liabilities Total | 134.9M | 297.6M | 218.7M | 155.8M | 34.7M | 57.7M | |
Property Plant And Equipment Gross | 107.2M | 112.4M | 149.7M | 162.1M | 103.9M | 109.1M | |
Total Current Assets | 405.5M | 659.7M | 398.8M | 300.3M | 94.3M | 175.7M | |
Accumulated Other Comprehensive Income | (2.4M) | 5.4M | (4.0M) | (8.4M) | (4.6M) | (4.4M) | |
Common Stock | 1.2M | 1.4M | 1.5M | 1.7M | 1.8M | 1.7M | |
Net Debt | (36.0M) | (89.2M) | (130.8M) | (57.3M) | (7.1M) | (7.5M) | |
Other Current Assets | 5.4M | 24.0M | 31.7M | 36.4M | 12M | 12.6M | |
Property Plant Equipment | 29.9M | 41.3M | 51.5M | 63.5M | 73.1M | 76.7M | |
Current Deferred Revenue | 38.7M | 96.6M | 85.7M | 51.8M | 59.5M | 62.5M | |
Intangible Assets | 53.2M | 58.1M | 53.8M | 50.7M | 58.3M | 61.3M | |
Other Liab | 93.7M | 259.2M | 174.6M | 116.9M | 134.4M | 141.1M | |
Net Tangible Assets | 340.1M | 397.3M | 281.9M | 206.7M | 237.7M | 227.0M | |
Retained Earnings Total Equity | (657.0M) | (778.0M) | (956.3M) | (1.1B) | (1.0B) | (982.0M) | |
Capital Surpluse | 1.1B | 1.3B | 1.3B | 1.5B | 1.7B | 873.1M | |
Inventory | (22.5M) | (50.5M) | (88.2M) | 1.0 | 0.9 | 0.95 | |
Deferred Long Term Liab | 6.6M | 7.2M | 6.6M | 6.3M | 7.2M | 9.3M |
Pair Trading with Sangamo Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sangamo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangamo Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Sangamo Stock
Moving against Sangamo Stock
0.85 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.79 | LLY | Eli Lilly | PairCorr |
0.79 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
0.74 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.67 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to Sangamo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sangamo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sangamo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sangamo Therapeutics to buy it.
The correlation of Sangamo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sangamo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sangamo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sangamo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sangamo Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Sangamo Stock, please use our How to Invest in Sangamo Therapeutics guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sangamo Therapeutics. If investors know Sangamo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sangamo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.24) | Revenue Per Share 0.066 | Quarterly Revenue Growth (0.95) | Return On Assets (0.58) | Return On Equity (1.94) |
The market value of Sangamo Therapeutics is measured differently than its book value, which is the value of Sangamo that is recorded on the company's balance sheet. Investors also form their own opinion of Sangamo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sangamo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sangamo Therapeutics' market value can be influenced by many factors that don't directly affect Sangamo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sangamo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sangamo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sangamo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.